Search
+
    SEARCHED FOR:

    CELLO WORLD LTD Q2 RESULTS

    Need to have one, strong brand or big market size: 4 midcap stocks with right levels of RoE and upside potential of up to 21%

    In all market conditions investing in mid-cap stocks is always a challenge for any investor. This challenge gets much bigger when the valuations are extremely high but at the same time the market is in a strong bullish trend. A choice has to be made between taking risk or losing the opportunity of making returns in a short period of time. In such times, it would be better that investors should be cautious in selecting the stocks, better to go with buying in smaller quantities and keep some cash allocated for the stocks, but only to be used on the day when there is absolutely chaos on the street. Why this strategy is likely to work, because it will take care of volatility which is bound to happen when valuations are not on the side of bulls. Refinitiv’s Stock Report Plus which lists stocks with high upside potential over the next 12 months, having an average recommendation rating of “buy” or "strong buy".

    10 Best Casseroles in India designed to Retain Heat for Extended Period (2024)

    Embark on a culinary journey with this curated selection of the best casseroles available online. From sleek stainless steel designs to innovative tri-ply construction, we showcase a range of options tailored to elevate your culinary experience. Discover casseroles with features like superior heat retention, and non-stick finishes. With capacities ranging from compact to generous, these casseroles ensure your dishes stay warm and flavourful, making mealtime a delightful experience every time.

    Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY

    Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.

    Hindalco Q4 Results: Profit jumps 70% YoY to Rs 1,412 crore, beats estimates

    Hindalco reported a 69.7% YoY jump in its standalone Q4 profit to Rs 1,412 crore with revenue rising 10.72% to Rs 22,140 crore, beating Street estimates. Consolidated EBITDA was Rs 7,201 crore, up 24% YoY, driven by lower costs and higher volumes.

    Q4 results today: ITC, IndiGo among 181 companies to announce earnings on Thursday

    181 companies, including IndiGo and ITC, will announce their quarterly earnings for Jan-Mar 2024. IndiGo is expected to post healthy earnings, while ITC may see muted revenue growth.

    Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24

    Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.

    The Economic Times
    BACK TO TOP
    Advertisement